bioRxiv Science⌕ Search

Biology subjects

Hermelo, I.

Publications and source records attributed to Hermelo, I..

3 recordsLinked to original sources

Multi-region whole-genome and transcriptomic profiling uncovers plastic, subclone-linked cell states in high-grade diffuse astrocytomas

Intratumoral heterogeneity is a defining feature of high-grade astrocytomas and a major contributor to treatment resistance. Yet how genomic diversification intersects with transcriptional plasticity remains incompletely understood. We performed high-resolution multi-omic profiling of three complex, treatment-naive tumors (two IDH-wildtype glioblastomas and one IDH-mutant grade 4 astrocytoma). By integrating whole-genome sequencing (WGS), bulk and single-cell RNA sequencing (scRNA-seq), and histopathology across four anatomically distinct regions per tumor, we mapped the co-evolution of genome and transcriptome. Despite striking regional differences in morphology and cellular states, genomic evolution was predominantly trunk-dominated. Most driver alterations were clonal across regions, indicating early acquisition and stable genomic backbones. The IDH-mutant tumor showed linear evolution with localized hypermutation, whereas glioblastomas displayed modest late-branching subclones. In contrast, transcriptional heterogeneity was pronounced and spatially structured. Distinct genetic subclones preferentially occupied divergent transcriptional states. However, subclones shared across regions frequently adopted different phenotypes depending on local microenvironment. Single-cell reconstruction from matched patient-derived cell lines resolved subclone-associated trajectories, revealing dynamic transitions between proliferative and inflammatory states. This study provides a framework for understanding how early-established genomic backbones and regional transcriptional plasticity jointly drive phenotypic diversity. While single biopsies may capture truncal drivers, resolving clinically relevant heterogeneity requires multi-region and single-cell approaches.

cancer biology↗

Sustained epithelial interferon signaling modulates incomplete pathologic response in colorectal cancer

Background & AimsPatients with colorectal cancer have heterogeneous clinical responses to chemotherapy, although clinical guidelines advise little variability in treatment selection based on molecular tumor features. Precision oncology research typically utilizes patient-derived tumor organoids (PDTO) to predict clinical outcomes, but such efforts are often not directed towards identification of molecular factors underlying differential responses to therapy. MethodsBulk RNA-sequencing was performed on treatment-naive PDTOs, and gene expression data was combined to drug sensitivity data to identify transcriptomic features associated with low in vitro sensitivity to chemotherapy. Whole-exome sequencing was performed on primary tumors to infer the somatic mutations of PDTOs and used to identify somatic mutations associated with differential in vitro drug responses. Publicly available gene expression and drug sensitivity data sets were used to validate the results. RNA interference was used for functional validation. ResultsPDTOs with low chemosensitivity had high JAK-STAT pathway activity resulting from high expression of interferon-stimulated genes. Evidence from single-cell RNA-sequencing confirmed chemotherapy-induced expression of interferon-stimulated genes in epithelial cells of cancers with partial response. EPSTI1 knockdown decreased cancer cell viability and sensitized cells to chemotherapy. ConclusionsSustained interferon signaling in epithelial cancer cells contributes to incomplete pathologic response in colorectal cancer. The findings highlight the potential of JAK-STAT inhibition or TRAIL pathway activation to enhance chemotherapy efficacy. Future studies investigating pharmacologic modulation of these pathways in preclinical CRC models are needed to determine their viability as therapeutic targets.

cancer biology↗

Androgen deprivation therapy-resistant club cells are linked to myeloid cell-driven immunosuppression in the prostate tumor microenvironment

Prostate cancer treatment resistance is a significant challenge facing the field. Genomic and transcriptomic profiling have partially elucidated the mechanisms through which cancer cells escape treatment, but their relation toward the tumor microenvironment (TME) remains elusive. Here we present a comprehensive transcriptomic landscape of the prostate TME at multiple points in the standard treatment timeline employing single-cell RNA-sequencing and spatial transcriptomics data from 110 patients. We identify club-like cells as a key epithelial cell subtype that acts as an interface between the prostate and the immune system. Tissue areas enriched with club-like cells have depleted androgen signaling and upregulated expression of luminal progenitor cell markers. Club-like cells display a senescence-associated secretory phenotype and their presence is linked to increased polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) activity. Our results indicate that club-like cells partake in inducing myeloid inflammation previously associated with androgen deprivation therapy resistance, providing a rationale for their therapeutic targeting.

cancer biology↗